WELLS FARGO & COMPANY/MN - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 105 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
WELLS FARGO & COMPANY/MN ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$61,564
-45.3%
52,172
-34.7%
0.00%
Q2 2023$112,601
+179.1%
79,859
+196.9%
0.00%
Q1 2023$40,345
+27.9%
26,896
-0.2%
0.00%
Q4 2022$31,532
+425.5%
26,950
+389.4%
0.00%
Q3 2022$6,000
-53.8%
5,507
-35.2%
0.00%
Q2 2022$13,000
-95.8%
8,505
-95.8%
0.00%
Q1 2022$312,000
-75.7%
203,010
-61.3%
0.00%
Q4 2021$1,286,000
-27.6%
524,841
-25.5%
0.00%
Q3 2021$1,776,000
+5820.0%
704,444
+6581.6%
0.00%
Q2 2021$30,000
+36.4%
10,543
+9.4%
0.00%
Q1 2021$22,000
-90.5%
9,633
-92.7%
0.00%
Q4 2020$231,000
+90.9%
131,322
+1.6%
0.00%
Q3 2020$121,000
-10.4%
129,236
-16.7%
0.00%
Q2 2020$135,000
-45.8%
155,101
-48.4%
0.00%
Q1 2020$249,000
+53.7%
300,371
+65.1%
0.00%
Q4 2019$162,000
+224.0%
181,953
+258.1%
0.00%
Q3 2019$50,00050,8060.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q3 2023
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$39,477,0003.01%
Raffles Associates 2,080,536$2,351,0002.51%
Defender Capital, LLC. 5,184,035$5,862,0002.30%
Prescott General Partners LLC 1,851,851$2,093,0000.16%
DAFNA Capital Management LLC 140,000$158,0000.04%
Fort Sheridan Advisors LLC 83,931$95,0000.03%
Long Focus Capital Management, LLC 215,000$243,0000.02%
XTX Topco Ltd 72,807$82,0000.02%
Ergoteles LLC 490,895$555,0000.02%
Beirne Wealth Consulting Services, LLC 45,000$51,0000.02%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders